Juno Therapeutics is a biopharma company developing novel cellular immunotherapies based on two distinct and complementary platforms: T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs) technologies.
Juno Therapeutics is a biopharma company developing novel cellular immunotherapies based on two distinct and complementary platforms: T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs) technologies.
Adaptimmune is focused on T cells to target and destroy cancer by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses.